Bonnet F, Burty C, Lewden C, et al. Changes in cancer mortality among hiv-infected patients: the mortalite 2005 survey. Clin Infect Dis. 2009;48(5):633–9. https://doi.org/10.1086/596766.

Article  PubMed  Google Scholar 

Monforte A, Abrams D, Pradier C, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-aids-defining malignancies. AIDS. 2008;22(16):2143–53. https://doi.org/10.1097/qad.0b013e3283112b77.

Article  PubMed  Google Scholar 

Fontela C, Aguinaga A, Moreno-Iribas C, et al. Trends and causes of mortality in a population-based cohort of HIV-infected adults in Spain: comparison with the general population. Sci Rep. 2020;10(1):8922. https://doi.org/10.1038/s41598-020-65841-0.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Nishijima T, Inaba Y, Kawasaki Y, et al. Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan. AIDS. 2020;34(6):913–21. https://doi.org/10.1097/qad.0000000000002498.

Article  PubMed  Google Scholar 

Kelly TA, Kim S, Jemmott LS, Jemmott JB 3rd. Predictors of colorectal cancer screening among African American men living with HIV. J Community Health. 2021;46(6):1099–106. https://doi.org/10.1007/s10900-021-00997-y.

Article  PubMed  Google Scholar 

Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol. 2011;12(9):905–12. https://doi.org/10.1016/s1470-2045(11)70056-0.

Article  PubMed  PubMed Central  Google Scholar 

NCCN Guidelines: cancer in people with HIV. National comprehensivesive cancer network. February 3, 2022; Version 1. https://www.nccn.org/guidelines/guidelines-detail?category=4&id=1487.

Casado JL, Machuca I, Bañon S, Morena A, Moltó J, Rodriguez MA. Raltegravir plus two nucleoside analogues as combination antiretroviral therapy in HIV-infected patients who require cancer chemotherapy. Antivir Ther. 2015;20:773–7. https://doi.org/10.3851/imp2961.

CAS  Article  PubMed  Google Scholar 

Olin JL, Klibanov O, Chan A, Spooner LM. Managing pharmacotherapy in people living with HIV and concomitant malignancy. Ann Pharmacother. 2019;53(8):812–32. https://doi.org/10.1177/1060028019833038.

Article  PubMed  Google Scholar 

D’Andrea F, Ceccarelli M, Facciolá A, Nunnari G, Pellicanò GF, Venanzi RE. Breast cancer in women living with HIV. Eur Rev Med Pharmacol Sci. 2019;23(3):1158–64. https://doi.org/10.26355/eurrev_201902_17007.

Article  PubMed  Google Scholar 

U.S. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. September 1, 2022. https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf..

Torres HA, Rallapalli V, Saxena A, et al. Efficacy and safety of antiretrovirals in HIV-infected patients with cancer. Clin Microbiol Infect. 2014;20(10):O672–9. https://doi.org/10.1111/1469-0691.12589.

CAS  Article  PubMed  Google Scholar 

Deeken JF, Tjen ALA, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis. 2012;55(9):1228–35. https://doi.org/10.1093/cid/cis613.

Article  PubMed  PubMed Central  Google Scholar 

Loulergue P, Merad M, Coriat R, et al. Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors. Invest New Drugs. 2017;35(2):247–9. https://doi.org/10.1007/s10637-016-0405-0.

CAS  Article  PubMed  Google Scholar 

Madeddu G, Menzaghi B, Ricci E, et al. Raltegravir central nervous system tolerability in clinical practice: results from a multicenter observational study. AIDS. 2012;26(18):2412–5. https://doi.org/10.1097/qad.0b013e32835aa141.

CAS  Article  PubMed  Google Scholar 

Shen YZ, Li TS. Interpretation of Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition). Int J Epidemiol Infect Dis. 2022;49(2):81–5.

Google Scholar 

Blazy A, Hennequin C, Gornet J, et al. Anal carcinomas in HIV-positive patients high-dose chemoradiotherapy is feasible in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2005;48(6):1176–81. https://doi.org/10.1007/s10350-004-0910-7.

Article  PubMed  Google Scholar 

Rubinstein PG, Moore PC, Rudek MA, Henry DH, Ramos JC, Ratner L, Reid E, Sharon E. Noy a, AIDS malignancy consortium (AMC). Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma. AIDS. 2018;32(5):605–11. https://doi.org/10.1097/QAD.0000000000001729.

CAS  Article  PubMed  Google Scholar 

Krown SE, Moser CB, MacPhail P, et al. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet. 2020;395(10231):1195–207. https://doi.org/10.1016/S0140-6736(19)33222-2.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, Vellone M, Giuliante F, Nuzzo G, Barone C. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol. 2004;15(6):933–9. https://doi.org/10.1093/annonc/mdh217.

CAS  Article  PubMed  Google Scholar 

Janinis J, Papakostas P, Samelis G, Skarlos D, Papagianopoulos P, Fountzilas G. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Ann Oncol. 2000;11(2):163–7. https://doi.org/10.1023/a:1008397109048.

CAS  Article  PubMed  Google Scholar 

Zhang X, Chen H, Lu Y, Xu C, Yao W, Xu L, Zhang R, Zhang L, Yao Q. Prevention of oxaliplatin-related neurotoxicity by ω-3 PUFAs. Medicine (Baltimore). 2020;99(50): e23564. https://doi.org/10.1097/MD.0000000000023564.

CAS  Article  Google Scholar 

Gui Q, Li D, Zhuge Y, Xu C. Efficacy of exercise rehabilitation program in relieving Oxaliplatin induced peripheral neurotoxicity. Asian Pac J Cancer Prev. 2021;22(3):705–9. https://doi.org/10.31557/APJCP.2021.22.3.705.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Fulco PP, Hynicka L, Rackley D. Raltegravir-based HAART regimen in a patient with large B-cell lymphoma. Ann Pharmacother. 2010;44(2):377–82. https://doi.org/10.1345/aph.1M370.

Article  PubMed  Google Scholar 

Rudek MA, Flexner C, Ambinder RF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet HIV. 2020;7(9):e602–10. https://doi.org/10.1016/S2352-3018(20)30073-4.

Article  Google Scholar 

Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP. Drug interactions between antineoplastic and antiretroviral therapies: implications and management for clinical practice. Crit Rev Oncol Hematol. 2009;72(1):10–20. https://doi.org/10.1016/j.critrevonc.2008.10.013.

Article  PubMed  Google Scholar 

Burger DM. Raltegravir: a review of its pharmacokinetics, pharmacology and clinical studies. Expert Opin Drug Metab Toxicol. 2010;6(9):1151–60. https://doi.org/10.1517/17425255.2010.513383.

CAS  Article  PubMed  Google Scholar 

Belkhir L, Seguin-Devaux C, Elens L, Pauly C, Gengler N, Schneider S, Ruelle J, Haufroid V, Vandercam B. Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients. Sci Rep. 2018;8(1):7359. https://doi.org/10.1038/s41598-018-25803-z.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Weller S, Borland J, Chen S, Johnson M, Savina P, Wynne B, Wajima T, Peppercorn AF, Piscitelli SC. Pharmacokinetics of dolutegravir in HIV-seronegative subjects with severe renal impairment. Eur J Clin Pharmacol. 2014;70(1):29–35. https://doi.org/10.1007/s00228-013-1590-9.

CAS  Article  PubMed  Google Scholar 

Belkhir L, Seguin-Devaux C, Elens L, et al. Impact of UGT1A1 polymorphisms on raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients. Sci Rep. 2018;8(1):7359. https://doi.org/10.1038/s41598-018-25803-z.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6(4):1205–18.

CAS  PubMed  Google Scholar 

Liu CY. Fluorouracil for allergic reactions to capecitabine. Ann Pharmacother. 2002;36(12):1897–9. https://doi.org/10.1345/aph.1C169.

Article  PubMed  Google Scholar 

Sombogaard F, Franssen EJF, Terpstra WE, Kerver ED, van den Berk GEL, Crul M. Outcome effects of antiretroviral drug combinations in HIV-positive patients with chemotherapy for lymphoma: a retrospective analysis. Int J Clin Pharm. 2018;40(5):1402–8. https://doi.org/10.1007/s11096-018-0620-1.

CAS  Article  PubMed  PubMed Central  Google Scholar 

Badowski ME, Burton B, Shaeer KM, Dicristofano J. Oral oncolytic and antiretroviral therapy administration: dose adjustments, drug interactions and other considerations for clinical use. Drugs Context. 2019;8:212550. https://doi.org/10.7573/dic.212550.

Article  PubMed  PubMed Central  Google Scholar